ClinicalTrials.gg

Program

cleminorexton

Its studies are mostly in Narcolepsy, led by Eli Lilly.

Furthest: phase 3, since Apr 27, 20261 company-led study, 1 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 3since Apr 27, 2026Apr 27, 2026Sep 30, 2027phase 3 · NCT07598708
  • Named in Eli Lilly’s own pipeline as Cleminorexton, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2026First study: phase 3 study in Disorders of Excessive SomnolenceFirst studyNCT07598708 · 222 planned · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in Disorders of Excessive SomnolenceNCT07598708

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07598708Disorders of Excessive Somnolence · United States3RecruitingSep 30, 2027222

How it is read

Names in the registry

  • “cleminorexton”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.